How Retatrutide Works: Mechanism and Pharmacology
How Retatrutide works: its target and mechanism as the sources state them, how long it acts, and what is still unknown.
- Class
- GLP-1 / GIP / glucagon triple agonist
- FDA status
- Not approved
- Investigational · phase 3
- Routes studied
- subcutaneous
- Half-life
- approximately 6 days
- subcutaneous, in people · Lancet 2022, PMID 36354040
How long it acts
Half-life values from FDA labels and published studies, by route. Animal values are labelled and do not describe people.
| Route | Half-life | Measured in | Source |
|---|---|---|---|
| subcutaneous | approximately 6 days | People | Lancet 2022, PMID 36354040 |
Full detail, including drug-testing windows, is on the Retatrutide half-life page.
The three receptors retatrutide acts on
LY3437943, the development name of retatrutide, is described as a single peptide that is an agonist at the glucagon, GIP and GLP-1 receptors.[2]
In laboratory (in vitro) testing, LY3437943 showed balanced glucagon-receptor and GLP-1-receptor activity but more GIP-receptor activity.[2]
What the extra receptors seem to add
In obese mice, the glucagon-receptor part added increased energy expenditure on top of calorie-intake reduction driven by the other two receptors.[2]
In human liver cells in a dish, glucagon and retatrutide both reduced ANGPTL3/8 secretion, and a glucagon-receptor blocking antibody prevented that.[3]
The authors of that lipid study suggest glucagon-receptor agonism could lower ANGPTL3/8 and so contribute to the triglyceride and LDL-C falls.[3]
What was seen in people
In adults with type 2 diabetes, higher retatrutide doses lowered perceived hunger and disinhibition compared with placebo, and larger weight loss went with lower hunger.[4]
In a liver substudy, liver-fat falls were related to body weight, abdominal fat and markers of insulin sensitivity and lipid metabolism.[5]
Total fat mass in the diabetes substudy fell by 26.1% on the pooled 8 mg groups and by 23.2% on 12 mg, versus 4.5% on placebo.[6]
Why the injections are weekly
In the phase 1b trial the pharmacokinetics were dose proportional and the half-life was about 6 days.[1]
The first-in-human summary said the pharmacokinetic profile supported weekly dosing, with weight reduction persisting to day 43 after a single dose.[2]
What is not yet shown in people
The 2 Oct 2026 PubMed ledger for retatrutide with energy-expenditure and metabolic-rate terms lists 6 human-only papers, so a direct human measurement of how much of the effect comes from each receptor is not described in the cached abstracts.
Calculated from source goals.json ledger, goal metabolism, retatrutide; human only 6; animal 4; date 2026-10-02. Formula: counts copied from the ledger query result
Related peptides
Common questions
How long does Retatrutide act in the body?
The half-life values we found are approximately 6 days (subcutaneous). A half-life is how long the amount in the body takes to fall by half; it is not the same as how long an effect lasts.
How does retatrutide work?
Retatrutide is a single peptide that activates the glucagon, GIP and GLP-1 receptors, and the animal and cell work attributes extra energy expenditure and lipid effects to the glucagon receptor.[2]
What is the half-life of retatrutide?
The phase 1b trial reported a half-life of approximately 6 days.[1]
More on Retatrutide
Sources
- 1LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.Lancet (London, England) · 2022PMID 36354040Accessed 2 Oct 2026
- 2LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.Cell metabolism · 2022PMID 35985340Accessed 2 Oct 2026
- 3Decreases in circulating ANGPTL3/8 concentrations following retatrutide treatment parallel reductions in serum lipids.Diabetes, obesity & metabolism · 2025PMID 40726454Accessed 2 Oct 2026
- 4Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study.Diabetes, obesity & metabolism · 2025PMID 40916752Accessed 2 Oct 2026
- 5Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.Nature medicine · 2024PMID 38858523Accessed 2 Oct 2026
- 6Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.The lancet. Diabetes & endocrinology · 2025PMID 40609566Accessed 2 Oct 2026
Found an error? Report a correction.